Relay Therapeutics (RLAY)

• Market cap: $420M
• 1 day: -5.34%
• 5 days: -16.78%
• 1 month: -22.50%
• 3 months: -42.33%
• 6 months: -62.14%
• Year to date: -42.33%
• 1 year: -69.08%
• 5 years: -92.92%
• 10 years: -92.92%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

441% more call options, than puts

Call options by funds: $606K | Put options by funds: $112K

149% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 35

22% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 36

20% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 6 (+1) [Q4]

3% more funds holding

Funds holding: 193 [Q3] → 199 (+6) [Q4]

2.63% less ownership

Funds ownership: 100.6% [Q3] → 97.96% (-2.63%) [Q4]

42% less capital invested

Capital invested by funds: $1.16B [Q3] → $676M (-$481M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $16 545% upside
• Avg. target: $19 666% upside
• High target: $23 827% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Robert Burns 18% 1-year accuracy 31 / 170 met price target	545% upside $16	Buy Reiterated	7 Mar 2025
Goldman Sachs Salveen Richter 24% 1-year accuracy 4 / 17 met price target	626% upside $18	Buy Maintained	27 Feb 2025
Stifel Bradley Canino 7% 1-year accuracy 2 / 28 met price target	827% upside $23	Buy Maintained	27 Feb 2025